The most recent research study by Polaris Market Research reveals that the GLP-1 analogues market is anticipated to flourish at a stable rate. With a projected CAGR of 21.3%, the market was valued ...

Surprising research strongly suggests semaglutide can help fight substance use disorder. Why aren't we using it?

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.

The MiDe systems, inspired by squid propulsion, demonstrate effective needle-free drug delivery in the gastrointestinal tract ...

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

New York, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

(MENAFN- GlobeNewsWire - Nasdaq) The ability to act upon more than one disease and disorder has led to the GLP-1 analogues market has been getting a tremendous boost globally in recent times.

The ability to act upon more than one disease and disorder has led to the GLP-1 analogues market has been getting a ...